In colon cancer cells for instance, LXRβ activates NLRP3 inflammasome by inducing Pannexin1-dependent ATP release and autocrine P2x7R activation, which in turn leads to anti-tumoral effect of LXR agonists (143) (Figure 1). This evidence concerns the gene NLRP3 and malignant colon neoplasm.